Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Ibrance Palbociclib Withdrawn
Adcetris Brentuximab vedotin Withdrawn
Cyramza Ramucirumab Cancelled
Venclexta Venetoclax Withdrawn
Admelog Insulin lispro Cancelled
Erbitux Cetuximab Cancelled
Translarna ataluren Cancelled
TBD Rituximab Cancelled
TBD Trastuzumab Cancelled